Opus Genetics entered into a Note Purchase Agreement for up to $155 million in senior secured notes. The facility consists of $105 million in committed capital and $50 million in uncommitted capital. An initial tranche of $35 million was funded on April 21, 2026. The notes mature on April 21, 2033. The debt is secured by substantially all assets of the company and its subsidiaries.